Drugs / InnoPCV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06497010 | Aug 2024 → Jul 2026 overdue | neoplasm | The Affiliated Hospital Of Guizhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | InnoPCV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06497010 ↗ |
| Modality | Messenger RNA (mRNA) | “Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV” NCT06497010 ↗ |